Search results
Results from the WOW.Com Content Network
This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Nausea is the most common side effect of semaglutide, the weight loss and diabetes medication often sold under the brand names ...
But some research has noted rare but serious side effects of once-weekly, 2.4-milligram (mg) semaglutide injections, such as pancreatitis, acute kidney injury, gallbladder issues, and thyroid cancer.
Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. [ 23 ] [ 24 ] [ 25 ] It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain .
Ozempic, Wegovy and Mounjaro may offer serious health benefits beyond weight loss. The GLP-1 medications have been linked to decreased risks of heart disease, kidney disease and Alzheimer’s ...
May worsen hormone sensitive conditions such as breast cancer, uterine cancer, ovarian cancer, endometriosis, and uterine fibroids. [17] Insomnia. [17] Goldenseal: orangeroot, yellow puccoon Hydrastis canadensis: Uterotonic [3] Greater celandine: celandine Chelidonium majus: Liver damage [4] Guarana: Paullinia cupana: Agitation and insomnia [3 ...
Nausea and vomiting are two of the most feared cancer treatment-related side-effects for people with cancer and their families. In 1983, Coates et al. found that people receiving chemotherapy ranked nausea and vomiting as the first and second most severe side-effects, respectively. [98]
The most commonly reported side effects of medications used for weight loss are nausea and constipation, but gallbladder and pancreatic disease are also reported. Makers of these drugs recommend ...
As of August 2014, a clinical trial administering sipuleucel-T in conjunction with ipilimumab (Yervoy) was tracking subjects but no longer enrolling new subjects; the trial evaluates the clinical safety and anti-cancer effects (quantified in PSA, radiographic and T cell response) of the combination therapy in patients with advanced prostate cancer.